Search results for: Market Access
Filter search results
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
This report analyses patient access in the UK to new medicines authorised via the centralised procedure between 2011 and 2016. The centralised procedure was created in 1995 to facilitate access…
We Asked, You Answered: Reflections on the First Round of MVAC Feedback
16 May 2019
Market-Driven, Value-Based Advanced Commitment (MVAC) is a new mechanism to help re-direct private-sector R&D investments where they’re needed most. We propose to use MVAC to encourage investments in tuberculosis (TB),…
Minimal Access Surgery – Why Don’t We Do More?
20 March 2018
OHE Consulting publishes a report on the barriers to the uptake of minimal access surgery in the NHS and private sector. Surgical practice has come a long way, barely recognisable…
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions
13 January 2020
…under the HST process could lead to inequalities in access and health outcomes for patients with ultra-rare conditions. A new OHE Consulting Report by Nadine Henderson, Maria Errea, Chris Skedgel,…
Barriers to Uptake of Minimal Access Surgery in the United Kingdom
1 March 2018
Surgical practice has and continues to develop at a tremendous pace, reflecting the evolving technological landscape as well as the expanding skillset of the surgical workforce. Minimal access surgery (MAS)…
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
…of access and uptake for NGS testing for lung cancer in Europe. We develop the health economic case for NGS testing and identify barriers and opportunities for widespread access to…
NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
7 January 2020
…third of these are ‘optimised’ recommendations. In this report we quantify the patient access associated with NICE ‘optimised’ recommendations. We evaluated optimised recommendations published between 2015 and 2019; 40 contained…
Altering the trajectory of HIV in Europe
22 May 2025
…access to care. Healthcare barriers: Limited access to testing and treatment in underserved groups, availability of medication, and healthcare provider biases contribute to gaps in testing and care. Policy and…
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…Published online June 2021. Accessed September 30, 2022. https://www.ace-hta.gov.sg/docs/default-source/process-methods/ace-drug-and-vaccine-evaluation-methods-and-process-guide-(june-2021).pdf Danish Medicines Council. The Danish Medicines Council Methods Guide For Assessing New Pharmaceuticals. Published online 2021. Accessed November 9, 2022. https://medicinraadet.dk/media/wq0dxny2/the_danish_medicines_council_methods_guide_for_assessing_new_pharmaceuticals_version_1-…